While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital Markets said a direct comparison of the two figures could be misleading given the shorter data collection time for Foundayo.
Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch